Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience

ATALAR, Banu; Ozsahin, Mahmut; Call, Jason; Napieralska, Aleksandra; Kamer, Serra; Villa, Salvador; Erpolat, ÖZGE; Negretti, Laura; Lassen-Ramshad, Yasmin; Onal, Cem; AKYÜREK, SERAP; UĞURLUER, Gamze; Baumert, Brigitta; Servagi-Vernat, Stephanie; Miller, Robert; ÖZYAR, Enis; Sio, Terence

doi:10.1016/j.radonc.2017.12.028

Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience

ATALAR B., Ozsahin M., Call J., Napieralska A., Kamer S., Villa S., ...Daha Fazla

RADIOTHERAPY AND ONCOLOGY, cilt.127, sa.1, ss.96-102, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 127 Sayı: 1
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.radonc.2017.12.028
Dergi Adı: RADIOTHERAPY AND ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.96-102
Anahtar Kelimeler: Adult medulloblastoma, Chemotherapy, Craniospinal, Multimodality, Radiotherapy, Rare Cancer Network (RCN), NONMETASTATIC MEDULLOBLASTOMA, ADJUVANT CHEMOTHERAPY, RISK MEDULLOBLASTOMA, SURVIVAL, MULTICENTER, RECURRENCE, STRATEGY
Gazi Üniversitesi Adresli: Evet

Özet

Background and purpose: The optimal treatment for adults with newly diagnosed medulloblastoma (MB) has not been defined. We report a large series of cases from the Rare Cancer Network.